AVTX
insider transactionsAvalo Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-318.8K
0 buy · 318.8K sell
Net value · 365d
-$6.3M
$0 in · $6.3M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
29
0 buy · 318.8K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·F
Chief Strategy Officer
$7.7K
588 sh · $13.10
Own -1%
-
Other·F
Chief Medical Officer
$14.2K
1.1K sh · $13.10
Own -2%
-
Other·F
Chief Financial Officer
$1.8K
138 sh · $13.10
Own -0%
-
Other·F
Chief Legal Officer
$14.2K
1.1K sh · $13.10
Own -3%
-
Grant·A
Director
$0
20.1K sh
Own New
-
Grant·A
Director
$0
20.1K sh
Own New
-
Grant·A
Director
$0
20.1K sh
Own New
-
Grant·A
Director
$0
20.1K sh
Own New
-
Grant·A
Director
$0
29.5K sh
Own New
-
Grant·A
Director
$0
20.1K sh
Own New
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
679 sh
Own +1%
-
Sell·S
Chief Medical Officer · 10b5-1
$10.9K
679 sh · $16.00
Own -1%
-
Exercise·M
Chief Medical Officer · 10b5-1
$5.5K
679 sh · $8.04
Own +1%
-
Grant·A
Chief Strategy Officer
$0
34.2K sh
Own +1288%
-
Grant·A
Chief Medical Officer
$0
43.5K sh
Own +1201%
-
Grant·A
Chief Financial Officer
$0
39.9K sh
Own +9433%
-
Grant·A
Chief Legal Officer
$0
24.3K sh
Own +669%
-
Grant·A
Chief Executive Officer
$0
100.2K sh
Own +111%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
3.0K sh
Own +2%
-
Sell·S
Chief Medical Officer · 10b5-1
$56.3K
3.0K sh · $18.76
Own -45%
-
Exercise·M
Chief Medical Officer · 10b5-1
$38.0K
3.0K sh · $12.65
Own +83%
-
Exercise·M
Chief Financial Officer · 10b5-1
$0
18.6K sh
Own +12%
-
Sell·S
Chief Financial Officer · 10b5-1
$448.8K
18.6K sh · $24.12
Own -98%
-
Exercise·M
Chief Financial Officer · 10b5-1
$183.8K
18.6K sh · $9.88
Own +4399%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
28.6K sh
Own +32%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
77.9K sh
Own +145%
-
Sell·S
Chief Medical Officer · 10b5-1
$230.1K
10.1K sh · $22.88
Own -74%
-
Sell·S
Chief Medical Officer · 10b5-1
$426.1K
19.0K sh · $22.41
Own -58%
-
Sell·S
Chief Medical Officer · 10b5-1
$952.7K
44.9K sh · $21.20
Own -58%
-
Sell·S
Chief Medical Officer · 10b5-1
$98.3K
5.0K sh · $19.65
Own -6%
-
Sell·S
Chief Medical Officer · 10b5-1
$496.4K
27.5K sh · $18.03
Own -25%
-
Exercise·M
Chief Medical Officer · 10b5-1
$230.3K
28.6K sh · $8.04
Own +35%
-
Exercise·M
Chief Medical Officer · 10b5-1
$985.5K
77.9K sh · $12.65
Own +2151%
-
Exercise·M
Chief Financial Officer · 10b5-1
$0
47.0K sh
Own +68%
-
Sell·S
Chief Financial Officer · 10b5-1
$200.9K
8.9K sh · $22.57
Own -95%
-
Sell·S
Chief Financial Officer · 10b5-1
$197.0K
9.2K sh · $21.37
Own -50%
-
Sell·S
Chief Financial Officer · 10b5-1
$56.1K
2.7K sh · $20.76
Own -13%
-
Sell·S
Chief Financial Officer · 10b5-1
$238.1K
12.3K sh · $19.28
Own -37%
-
Sell·S
Chief Financial Officer · 10b5-1
$256.7K
13.8K sh · $18.55
Own -29%
-
Exercise·M
Chief Financial Officer · 10b5-1
$377.9K
47.0K sh · $8.04
Own +11111%
-
Sell·S
Director · 10b5-1
$72.5K
3.2K sh · $22.88
Own -50%
-
Exercise·M
Chief Legal Officer · 10b5-1
$0
12.6K sh
Own +17%
-
Exercise·M
Chief Legal Officer · 10b5-1
$0
62.5K sh
Own +250%
-
Sell·S
Chief Legal Officer · 10b5-1
$9.5K
400 sh · $23.71
Own -10%
-
Sell·S
Chief Legal Officer · 10b5-1
$210.0K
9.3K sh · $22.70
Own -70%
-
Sell·S
Chief Legal Officer · 10b5-1
$484.5K
22.8K sh · $21.22
Own -63%
-
Sell·S
Chief Legal Officer · 10b5-1
$102.8K
5.2K sh · $19.78
Own -13%
-
Sell·S
Chief Legal Officer · 10b5-1
$706.8K
37.4K sh · $18.91
Own -47%
-
Exercise·M
Chief Legal Officer · 10b5-1
$101.0K
12.6K sh · $8.04
Own +19%
-
Exercise·M
Chief Legal Officer · 10b5-1
$839.4K
62.5K sh · $13.43
Own +1720%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
679 sh
Own +0%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
1.0K sh
Own +0%
-
Sell·S
Chief Medical Officer · 10b5-1
$26.9K
1.7K sh · $16.00
Own -32%
-
Exercise·M
Chief Medical Officer · 10b5-1
$5.5K
679 sh · $8.04
Own +15%
-
Exercise·M
Chief Medical Officer · 10b5-1
$12.7K
1.0K sh · $12.65
Own +28%
-
Sell·S
Chief Financial Officer · 10b5-1
$111.9K
8.5K sh · $13.23
Own -95%
-
Sell·S
Chief Financial Officer · 10b5-1
$110.7K
8.5K sh · $13.09
Own -49%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
4.0K sh
Own +2%
-
Sell·S
Chief Medical Officer · 10b5-1
$71.5K
4.0K sh · $18.01
Own -52%
-
Exercise·M
Chief Medical Officer · 10b5-1
$50.2K
4.0K sh · $12.65
Own +110%
-
Sell·S
Chief Financial Officer · 10b5-1
$31.3K
1.8K sh · $17.57
Own -9%
-
Sell·S
Chief Financial Officer · 10b5-1
$105.6K
6.2K sh · $17.02
Own -24%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
679 sh
Own +0%
-
Sell·S
Chief Medical Officer · 10b5-1
$10.9K
679 sh · $16.00
Own -16%
-
Exercise·M
Chief Medical Officer · 10b5-1
$5.5K
679 sh · $8.04
Own +19%
-
Sell·S
Chief Financial Officer · 10b5-1
$125.8K
7.5K sh · $16.83
Own -23%
-
Sell·S
Chief Financial Officer · 10b5-1
$7.9K
500 sh · $15.86
Own -2%
-
Grant·A
Director
$16.2K
1.3K sh · $12.13
Own New
-
Grant·A
Director
$16.6K
1.4K sh · $12.13
Own New
-
Exercise·M
Director
$0
3.2K sh
Own +316600%
-
Exercise·M
Director
—
3.2K sh
Own +100%
-
Exercise·M
Director
$0
3.2K sh
Own +316600%
-
Exercise·M
Director
—
3.2K sh
Own New
-
Exercise·M
Director
$0
3.2K sh
Own +316600%
-
Exercise·M
Director
—
3.2K sh
Own +100%
-
Exercise·M
Chief Financial Officer
$0
24.2K sh
Own New
-
Other·F
Chief Financial Officer
$114.5K
8.2K sh · $13.89
Own -20%
-
Exercise·M
Chief Financial Officer
—
24.2K sh
Own +140%
-
Exercise·M
Director
$0
3.2K sh
Own +316600%
-
Exercise·M
Director
—
3.2K sh
Own +100%
-
Exercise·M
Chief Executive Officer
$0
64.9K sh
Own +6486600%
-
Other·F
Chief Executive Officer
$304.1K
21.9K sh · $13.89
Own -20%
-
Exercise·M
Chief Executive Officer
—
64.9K sh
Own +138%
-
Exercise·M
Director
$0
3.2K sh
Own +316600%
-
Exercise·M
Director
—
3.2K sh
Own +100%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
6.0K sh
Own +4%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
19.5K sh
Own +10%
-
Sell·S
Chief Medical Officer · 10b5-1
$411.6K
25.5K sh · $16.15
Own -88%
-
Exercise·M
Chief Medical Officer · 10b5-1
$48.2K
6.0K sh · $8.04
Own +26%
-
Exercise·M
Chief Medical Officer · 10b5-1
$246.7K
19.5K sh · $12.65
Own +538%
-
Grant·A
Chief Business Officer
$0
95.0K sh
Own New
-
Grant·A
Chief Strategy Officer
$0
95.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
105.0K sh
Own New
-
Grant·A
Chief Financial Officer
$0
105.0K sh
Own New
-
Grant·A
Chief Legal Officer
$0
80.0K sh
Own New
-
Grant·A
Chief Executive Officer
$0
286.0K sh
Own New
-
Grant·A
Director
$12.5K
848 sh · $14.74
Own New
-
Grant·A
Director
$15.4K
1.0K sh · $14.74
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 10, 2026 | Jennifer Riley | Other F | 588 | $7.7K |
| Jun 10, 2026 | Mittie Doyle | Other F | 1.1K | $14.2K |
| Jun 10, 2026 | Christopher Ryan Sullivan KEY | Other F | 138 | $1.8K |
| Jun 10, 2026 | Paul Varki | Other F | 1.1K | $14.2K |
| Jun 2, 2026 | Samantha Truex | Grant A | 20.1K | $0 |
| Jun 2, 2026 | Aaron Kantoff | Grant A | 20.1K | $0 |
| Jun 2, 2026 | Rita Jain | Grant A | 20.1K | $0 |
| Jun 2, 2026 | Kevin Robert Lind | Grant A | 20.1K | $0 |
| Jun 2, 2026 | Michael Thomas Heffernan | Grant A | 29.5K | $0 |
| Jun 2, 2026 | Gilla Kaplan | Grant A | 20.1K | $0 |
| May 28, 2026 | Mittie Doyle 10b5-1 | Exercise M | 679 | $0 |
| May 28, 2026 | Mittie Doyle 10b5-1 | Sell S | 679 | $10.9K |
| May 28, 2026 | Mittie Doyle 10b5-1 | Exercise M | 679 | $5.5K |
| May 21, 2026 | Jennifer Riley | Grant A | 34.2K | $0 |
| May 21, 2026 | Mittie Doyle | Grant A | 43.5K | $0 |
| May 21, 2026 | Christopher Ryan Sullivan KEY | Grant A | 39.9K | $0 |
| May 21, 2026 | Paul Varki | Grant A | 24.3K | $0 |
| May 21, 2026 | Garry Arthur Neil KEY | Grant A | 100.2K | $0 |
| May 15, 2026 | Mittie Doyle 10b5-1 | Exercise M | 3.0K | $0 |
| May 15, 2026 | Mittie Doyle 10b5-1 | Sell S | 3.0K | $56.3K |
| May 15, 2026 | Mittie Doyle 10b5-1 | Exercise M | 3.0K | $38.0K |
| May 7, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Exercise M | 18.6K | $0 |
| May 7, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Sell S | 18.6K | $448.8K |
| May 7, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Exercise M | 18.6K | $183.8K |
| May 6, 2026 | Mittie Doyle 10b5-1 | Exercise M | 28.6K | $0 |
| May 6, 2026 | Mittie Doyle 10b5-1 | Exercise M | 77.9K | $0 |
| May 6, 2026 | Mittie Doyle 10b5-1 | Sell S | 10.1K | $230.1K |
| May 6, 2026 | Mittie Doyle 10b5-1 | Sell S | 19.0K | $426.1K |
| May 6, 2026 | Mittie Doyle 10b5-1 | Sell S | 44.9K | $952.7K |
| May 6, 2026 | Mittie Doyle 10b5-1 | Sell S | 5.0K | $98.3K |
| May 6, 2026 | Mittie Doyle 10b5-1 | Sell S | 27.5K | $496.4K |
| May 6, 2026 | Mittie Doyle 10b5-1 | Exercise M | 28.6K | $230.3K |
| May 6, 2026 | Mittie Doyle 10b5-1 | Exercise M | 77.9K | $985.5K |
| May 6, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Exercise M | 47.0K | $0 |
| May 6, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Sell S | 8.9K | $200.9K |
| May 6, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Sell S | 9.2K | $197.0K |
| May 6, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Sell S | 2.7K | $56.1K |
| May 6, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Sell S | 12.3K | $238.1K |
| May 6, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Sell S | 13.8K | $256.7K |
| May 6, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Exercise M | 47.0K | $377.9K |
| May 6, 2026 | Mitchell Chan 10b5-1 | Sell S | 3.2K | $72.5K |
| May 6, 2026 | Paul Varki 10b5-1 | Exercise M | 12.6K | $0 |
| May 6, 2026 | Paul Varki 10b5-1 | Exercise M | 62.5K | $0 |
| May 6, 2026 | Paul Varki 10b5-1 | Sell S | 400 | $9.5K |
| May 6, 2026 | Paul Varki 10b5-1 | Sell S | 9.3K | $210.0K |
| May 6, 2026 | Paul Varki 10b5-1 | Sell S | 22.8K | $484.5K |
| May 6, 2026 | Paul Varki 10b5-1 | Sell S | 5.2K | $102.8K |
| May 6, 2026 | Paul Varki 10b5-1 | Sell S | 37.4K | $706.8K |
| May 6, 2026 | Paul Varki 10b5-1 | Exercise M | 12.6K | $101.0K |
| May 6, 2026 | Paul Varki 10b5-1 | Exercise M | 62.5K | $839.4K |
| May 5, 2026 | Mittie Doyle 10b5-1 | Exercise M | 679 | $0 |
| May 5, 2026 | Mittie Doyle 10b5-1 | Exercise M | 1.0K | $0 |
| May 5, 2026 | Mittie Doyle 10b5-1 | Sell S | 1.7K | $26.9K |
| May 5, 2026 | Mittie Doyle 10b5-1 | Exercise M | 679 | $5.5K |
| May 5, 2026 | Mittie Doyle 10b5-1 | Exercise M | 1.0K | $12.7K |
| Apr 30, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Sell S | 8.5K | $111.9K |
| Apr 29, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Sell S | 8.5K | $110.7K |
| Apr 6, 2026 | Mittie Doyle 10b5-1 | Exercise M | 4.0K | $0 |
| Apr 6, 2026 | Mittie Doyle 10b5-1 | Sell S | 4.0K | $71.5K |
| Apr 6, 2026 | Mittie Doyle 10b5-1 | Exercise M | 4.0K | $50.2K |
| Apr 2, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Sell S | 1.8K | $31.3K |
| Apr 2, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Sell S | 6.2K | $105.6K |
| Apr 1, 2026 | Mittie Doyle 10b5-1 | Exercise M | 679 | $0 |
| Apr 1, 2026 | Mittie Doyle 10b5-1 | Sell S | 679 | $10.9K |
| Apr 1, 2026 | Mittie Doyle 10b5-1 | Exercise M | 679 | $5.5K |
| Apr 1, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Sell S | 7.5K | $125.8K |
| Apr 1, 2026 | Christopher Ryan Sullivan KEY 10b5-1 | Sell S | 500 | $7.9K |
| Mar 31, 2026 | Rita Jain | Grant A | 1.3K | $16.2K |
| Mar 31, 2026 | Kevin Robert Lind | Grant A | 1.4K | $16.6K |
| Mar 28, 2026 | Samantha Truex | Exercise M | 3.2K | $0 |
| Mar 28, 2026 | Samantha Truex | Exercise M | 3.2K | — |
| Mar 28, 2026 | Jonathan Goldman | Exercise M | 3.2K | $0 |
| Mar 28, 2026 | Jonathan Goldman | Exercise M | 3.2K | — |
| Mar 28, 2026 | Aaron Kantoff | Exercise M | 3.2K | $0 |
| Mar 28, 2026 | Aaron Kantoff | Exercise M | 3.2K | — |
| Mar 28, 2026 | Christopher Ryan Sullivan KEY | Exercise M | 24.2K | $0 |
| Mar 28, 2026 | Christopher Ryan Sullivan KEY | Other F | 8.2K | $114.5K |
| Mar 28, 2026 | Christopher Ryan Sullivan KEY | Exercise M | 24.2K | — |
| Mar 28, 2026 | Mitchell Chan | Exercise M | 3.2K | $0 |
| Mar 28, 2026 | Mitchell Chan | Exercise M | 3.2K | — |
| Mar 28, 2026 | Garry Arthur Neil KEY | Exercise M | 64.9K | $0 |
| Mar 28, 2026 | Garry Arthur Neil KEY | Other F | 21.9K | $304.1K |
| Mar 28, 2026 | Garry Arthur Neil KEY | Exercise M | 64.9K | — |
| Mar 28, 2026 | Gilla Kaplan | Exercise M | 3.2K | $0 |
| Mar 28, 2026 | Gilla Kaplan | Exercise M | 3.2K | — |
| Mar 16, 2026 | Mittie Doyle 10b5-1 | Exercise M | 6.0K | $0 |
| Mar 16, 2026 | Mittie Doyle 10b5-1 | Exercise M | 19.5K | $0 |
| Mar 16, 2026 | Mittie Doyle 10b5-1 | Sell S | 25.5K | $411.6K |
| Mar 16, 2026 | Mittie Doyle 10b5-1 | Exercise M | 6.0K | $48.2K |
| Mar 16, 2026 | Mittie Doyle 10b5-1 | Exercise M | 19.5K | $246.7K |
| Feb 26, 2026 | Taylor Boyd | Grant A | 95.0K | $0 |
| Feb 26, 2026 | Jennifer Riley | Grant A | 95.0K | $0 |
| Feb 26, 2026 | Mittie Doyle | Grant A | 105.0K | $0 |
| Feb 26, 2026 | Christopher Ryan Sullivan KEY | Grant A | 105.0K | $0 |
| Feb 26, 2026 | Paul Varki | Grant A | 80.0K | $0 |
| Feb 26, 2026 | Garry Arthur Neil KEY | Grant A | 286.0K | $0 |
| Dec 31, 2025 | Kevin Robert Lind | Grant A | 848 | $12.5K |
| Dec 31, 2025 | Rita Jain | Grant A | 1.0K | $15.4K |
About AVTX insider trading
This page tracks insider transactions for Avalo Therapeutics, Inc. (AVTX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.